Study of AGEN1884 With Pembrolizumab in 1L NSCLC

Summary

A Phase IIa Open-Label Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with Pembrolizumab in Subjects with Chemotherapy Naïve, PD-L1 high, metastatic Non-Small Cell Lung Cancer (NSCLC)

Timeline

Start

2017-10-04

Primary completion

2018-05-01

Completion

2019-03-01

Drugs

Indications